By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ViiV Healthcare 

Five Moore Drive

Research Triangle Park  North Carolina  27709-3398  U.S.A.
Phone: 877-844-8872 Fax: n/a


Company News
ViiV Healthcare Launches Phase III Programme Evaluating A Two-Drug Regimen Combining Dolutegravir And Lamivudine For HIV-1 Treatment 8/16/2016 8:21:30 AM
ViiV Healthcare Release: ARIA Study Shows Superior Efficacy Of Triumeq For Treatment-Naïve Women Living With HIV 7/18/2016 6:10:34 AM
ViiV Healthcare Announces FDA Approval To Lower The Weight Limit For Dolutegravir In Children And Adolescents Living With HIV 6/10/2016 9:36:25 AM
ViiV Healthcare And The International Association Of Providers Of AIDS Care (IAPAC) To Collaborate On Fast-Track Cities 5/31/2016 10:04:51 AM
ViiV Healthcare, Medicines Patent Pool Extend Licence For Dolutegravir To All Lower Middle-Income Countries 4/25/2016 7:25:58 AM
ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir 2/25/2016 6:06:48 AM
ViiV Healthcare Announces Phase II Study Results For First Two Drug, Long-Acting Injectable Regimen For HIV-1 Treatment 2/24/2016 6:35:03 AM
Bristol-Myers Squibb (BMY) Completes Previously Announced Sale Of Its HIV R&D Portfolio To ViiV Healthcare 2/22/2016 12:09:03 PM
GlaxoSmithKline (GSK)'s Global HIV Business ViiV Healthcare Completes Transactions To Acquire Bristol-Myers Squibb (BMY)'s R&D HIV Assets 2/22/2016 10:26:00 AM
ViiV Healthcare To Progress Collaboration With Janssen To Develop The First Long-Acting, Two Drug Injectable Regimen For Treatment Of HIV-1 Infection 1/7/2016 6:55:21 AM